Tau imaging probe
US-9452985-B2 · Sep 27, 2016 · US
PSMA-binding agents and uses thereof
US10500292B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10500292-B2 |
| Application number | US-201815864236-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 8, 2018 |
| Priority date | Aug 1, 2008 |
| Publication date | Dec 10, 2019 |
| Grant date | Dec 10, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of preparing a compound of the formula: the method comprising contacting a compound of the formula: with TFA, wherein each instance of PMB is p-methoxybenzyl. 2. The method of claim 1 further comprising contacting a compound of the formula: with a compound of the formula: to provide the compound of the formula: 3. A method of preparing a compound of the formula: the method comprising contacting a compound of the formula: with K 18 F and K222. 4. The method of claim 3 further comprising contacting a compound of the formula: with a compound of the formula: and NEt 3 to provide the compound of the formula:
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
of a saturated carbon skeleton containing rings · CPC title
Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10500292B2 cover?
- Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron…
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0455. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).